(11) EP 3 868 221 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

25.08.2021 Bulletin 2021/34

(51) Int CI.:

A24B 13/00 (2006.01)

A24B 15/16 (2020.01)

(21) Application number: 20158075.0

(22) Date of filing: 18.02.2020

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated Extension States:

BA ME

Designated Validation States:

KH MA MD TN

- (71) Applicant: NERUDIA LIMITED
 Liverpool Merseyside L24 9HP (GB)
- (72) Inventor: The designation of the inventor has not yet been filed
- (74) Representative: Mewburn Ellis LLP
 Aurora Building
 Counterslip
 Bristol BS1 6BX (GB)

(54) SMOKELESS ARTICLE

(57) A smokeless article for oral consumption comprising a pouch is described. The pouch encloses a content which comprises nicotine-dosed bamboo fibres. The

bamboo fibres have a particle size of 10-500 $\mu m.$ The smokeless article may be used for the oral delivery of nicotine to a consumer.




Figure 5

EP 3 868 221 A1

Description

Field of the Disclosure

[0001] The present disclosure relates to a smokeless article. In particular, the disclosure relates to a smokeless article comprising nicotine-dosed bamboo fibres, wherein the bamboo fibres have a particle size of 10-500 μm.

Background

15

30

35

50

[0002] Smoking is generally considered to expose a smoker to potentially harmful substances. It is generally thought that the majority of the potentially harmful substances are formed by the heat generated during burning (combustion) of the article. There is interest in so-called heat not burn products, which heat a tobacco or similar substrate at a lower temperature than a conventional cigarette. These products are usually described as less harmful than conventional cigarettes. Both conventional cigarettes and heat not burn products are visible during use and produce smoke or vapour.

[0003] As a result of these considerations and because of consumer preferences, it is desirable to find and improve alternative substance delivery routes that continue to meet user expectations. Smokeless articles are a suitable alternative because they do not require heating for substance delivery to the user. Instead, smokeless articles rely on saliva to extract soluble substances, typically nicotine and/or flavours, from tobacco contained within the smokeless article.

[0004] Conventional smokeless articles have a saliva permeable pouch housing a content. The content is generally in the form of tobacco, said tobacco containing a soluble element, typically nicotine. Such a product may be referred to as portion snus. It is typically provided as prepackaged (traditionally moist) powder in small teabag-like pouches. Each pouch is a single portion or unit. This moistened product may be referred to as original snus.

[0005] Smokeless articles are placed in the mouth where saliva extracts the soluble element from the tobacco contained within. Typically, the smokeless article is placed in the oral cavity, sublingually or in the oral vestibule (between the teeth and lips/cheeks). The user may assist extraction by oral manipulation, such as by chewing and/or sucking or pressing on the outside of the mouth to squeeze the pouch.

[0006] The resulting saliva, which contains extracts, subsequently contacts a mucous membrane in the mouth, or at another point of the gastrointestinal tract, to deliver the soluble element across the membrane and into the bloodstream. The soluble element is then transported by the bloodstream to the site of action. For example, nicotine is delivered to the brain where it acts upon acetylcholine receptors.

[0007] The above described extraction and delivery process continues until the soluble element is depleted from the smokeless article. The smokeless article must then be removed from the mouth and disposed of.

[0008] Some commercially available smokeless articles contain snuff. Snuff is smokeless tobacco made from ground or pulverised tobacco leaves. Snuff is available in dry form or wet (moist) form. Moist snuff may be referred to as snus. Two common varieties of snus are Scandinavian snus and American snus. Both varieties of snus are available in a loose form, but are often contained within a saliva permeable pouch.

[0009] Typically, production of snus is achieved by grinding a blend of leaf tobaccos to specified particle sizes. The ground tobacco is then mixed with water and sodium chloride in closed process blenders. The mixture is subjected to a heat treatment, involving temperatures up to 80 - 100 °C, for several hours to pasteurize the snus. Thereafter, the snus is cooled and other ingredients may be added. Snus is typically manufactured to meet the GothiaTek® standard, as detailed in "Swedish snus and the GothiaTek® standard" (2005), Rutqvist, et al.

[0010] The World Health Organisation states that smokeless articles are considerably less hazardous than cigarettes. Action on Smoking and Health considers smokeless articles to be about one hundred times less harmful than cigarettes. Smokeless articles are therefore thought to provide a healthier alternative for smokers.

[0011] There is a need for improved design of smokeless articles to enhance the user experience and improve the function of its constituent components.

[0012] The present disclosure has been devised in the light of the above considerations.

Summary of the Disclosure

[0013] At its most general, the present disclosure relates to a smokeless article e.g. a snus article for oral use.

[0014] According to a first aspect, there is provided a smokeless article for oral consumption comprising a pouch enclosing a content, the content comprising nicotine-dosed bamboo fibres, wherein the bamboo fibres have a particle size of 10-500 μ m.

[0015] A smokeless article comprising bamboo fibres of a particle size within this range provides an unexpectedly high nicotine release rate from the article. A higher nicotine release rate provides a more effective product which is more desirable to some consumers. Aside from this, the bamboo fibres provide the product with a paler appearance which increases the eye appeal of the product to consumers.

[0016] In some embodiments, the bamboo fibres have a particle size of 10-450 μ m, for example 10-400 μ m, 10-350 μ m, 10-300 μ m, 10-250 μ m, 10-200 μ m, 10-150 μ m, 10-100 μ m, 10-50 μ m, 15-50 μ m, 15-45 μ m, 20-50 μ m, 20-45 μ m, 20-40 μ m or 25-35 μ m. In some embodiments, the bamboo fibres have a particle size of about 30 μ m.

[0017] In some embodiments, the bamboo fibres have a particle size of 15-500 μ m, for example 20-500 μ m, 50-500 μ m, 100-500 μ m, 150-500 μ m, 200-500 μ m, 250-500 μ m, 250-450 μ m, 250-400 μ m, 250-350 μ m, 260-340 μ m, 270-330 μ m, 280-320 μ m, 290-310 μ m or 295-305 μ m. In some embodiments, the bamboo fibres have a particle size of about 300 μ m.

[0018] In some embodiments, the bamboo fibres have a particle size of 30-300 μ m.

[0019] In some embodiments, the nicotine-dosed bamboo fibres comprise a nicotinic compound selected from nicotine, nicotine salt(s), nicotine complex(es); and nicotine solvate(s). In some embodiments, the nicotinic compound is provided in a plant material. In some embodiments, the plant material is tobacco.

[0020] In some embodiments, the smokeless article is tobacco-free.

30

35

40

50

[0021] In this way, the user may experience a similar or enhanced recreational/pharmaceutical effect as compared to conventional tobacco-containing products without experiencing undesirable components inherent to tobacco (e.g. tobacco flavour).

[0022] In some embodiments, the total nicotine content is from 5 to 15 mg. In some embodiments, the total nicotine content is about 10 mg.

[0023] In some embodiments, greater than 75 wt%, preferably greater than 80 wt%, of the total nicotine content of the smokeless article is released from the smokeless article after 20 minutes immersed in water.

[0024] Another aspect of the invention is the use of nicotine-dosed bamboo fibres, wherein the bamboo fibres have a particle size of 10-500 μ m, as a nicotine release accelerant in a smokeless article for oral consumption. In some embodiments, the smokeless article is according to the first aspect.

[0025] Another aspect of the invention is the use of nicotine-dosed bamboo fibres, wherein the bamboo fibres have a particle size of 10-500 μ m, to increase manufacturing capacity of a smokeless article and/or reduce manufacturing cost. In some embodiments, the smokeless article is according to the first aspect.

[0026] The use of bamboo fibres of a relatively small particle size in the range 10-500 μ m means that the particulate bamboo fibre feedstock has a higher bulk density than a corresponding bamboo fibre feedstock of a larger particle size. This means that during manufacture of the product, the feedstock occupies a smaller volume and a larger mass of fibres may be processed per unit time. This increases manufacturing capacity, reducing the overall production cost for the product and increasing efficiency of the manufacturing process.

[0027] A further reduction in manufacturing cost and increase in efficiency is achieved by the smokeless article of the invention due to the higher density of the bamboo fibre feedstock. The higher density means that the pouch may be smaller while still carrying the same mass of fibre. This means that the amount of material used to manufacture the pouch per smokeless article is reduced, which reduces manufacturing cost.

[0028] Thus a second aspect of the invention is a process of manufacturing the smokeless article according to the first aspect, comprising the steps of;

- (i) forming one or more sheets of pouch material around the contents; and
- (ii) thermally or chemically sealing the pouch material to enclose the contents.

[0029] Another aspect of the invention is a kit comprising a plurality of smokeless articles according to the first aspect and a container.

[0030] As used herein, the term "particle size" when referring to fibres such as bamboo fibres indicates the maximum size of the longest dimension of the fibres. For example, a particle size of 50 μ m indicates that in the population of fibres, the maximum fibre length is 50 μ m.

[0031] Particles having the desired particle size may be obtained by passing a population of fibres through a sieve of corresponding mesh size. For example, to obtain fibres of particle size 300 μ m (i.e. a maximum fibre length of 300 μ m), a population of fibres are passed through a sieve with 300 μ m diameter apertures in the mesh. In this way, fibres with a length of 300 μ m or less pass through the mesh and fibres longer than 300 μ m are retained by the mesh. The fibres which pass through the mesh may then be used in the smokeless article of the invention, having a particle size of 300 μ m. Fibres of a desired particle size are also available from commercial suppliers such as Jelu-werk.

[0032] As used herein, the term "bamboo fibres" refers to natural fibres from plants of the Bambusoideae subfamily of the *Poaceae* family of grasses. The fibres may originate from any part of the plant, but in some embodiments may be originate from the stem of the plant. The fibres may be obtained from commercial sources such as JELUCEL® BF fibres sold by Jelu-werk, or may be prepared by grinding or milling plant material until fibers of the required particle size are obtained.

[0033] As used herein, the term "nicotine-dosed bamboo fibres" refers to a composition comprising bamboo fibres

and a nicotinic compound. The nicotinic compound may be added to or mixed with the bamboo fibres prior to incorporation into the smokeless article. In some embodiments, the bamboo fibres are loaded into a suitable dryer, sprayed with a solution of nicotinic compound and dried to form nicotine-dosed bamboo fibres. The dryer may be a fluidised bed dryer. The solution may be a solution of nicotinic compound in glycerin. In some embodiments, the solution of nicotinic compound in glycerin may comprise from 10 to 50 wt% nicotinic compound based on the total solution weight, for example from 10 to 40 wt% or from 10 to 30 wt%.

[0034] The nicotinic compound may be selected from nicotine, nicotine salt(s), nicotine complex(es); and nicotine solvate(s). Alternatively or additionally, the nicotinic compound may be present within a plant material such as tobacco. Thus the nicotine-dosed bamboo fibres may comprise or consist of a mixture of bamboo fibres and tobacco.

[0035] As used herein, the term "saliva" is intended to refer to the liquid substance formed in the mouth of animals, such as humans, that includes water, electrolytes and enzymes. Other components of saliva may include mucus, white blood cells, epithelial cells and/or antimicrobial agents.

[0036] As used herein, the term "saliva-soluble" is intended to refer to compounds, ingredients, or any other substances which can dissolve in saliva present in the oral cavity of the user at physiological temperature. Such substances may include, for example, nicotine and/or flavours. In some cases a standard commercially available artificial saliva may be used to test saliva solubility. Alternatively, "saliva-soluble" may equate to "water-soluble" and refer to compounds, ingredients, or any other substances which can dissolve in water present in the oral cavity of the user at physiological temperature.

[0037] As used herein, the term "plant material" is intended to refer to a portion and/or part(s) of a plant (e.g. leaf, stem, flower or bud). The plant material may be processed (for example, by shredding, grinding or drying) or it may be non-processed (that is, used whole). The plant material is typically fibrous (comprising or characterised by fibres). For the avoidance of doubt, the term "plant material" is not intended to include pulp and/or paper which is derived from a plant material (typically wood) and chemically and/or mechanically processed to extract fibres before use.

[0038] As used herein, the term "moisture content" may include water, humectants, liquid flavourants and/or other liquid compounds.

[0039] As used herein, the term "oral consumption" is intended to refer to any oral administration route achieved by placing the smokeless article into the oral cavity. This includes, but is not limited to, buccal, sub-lingual, periodontal, gingival and ingestion.

[0040] The smokeless article may be described as a snus article.

35

45

50

[0041] The smokeless article comprises a pouch having a contents, wherein the contents (e.g. bamboo fibres) is completely enclosed by the pouch. The pouch is sealed to ensure that the contents of the pouch does not scatter inside the mouth.

[0042] The smokeless article preferably has a mass of about 0.1 g to 5.0 g, such as about 0.5 g to about 4.0 g or about 1.0 g to about 3.0 g.

[0043] The smokeless article preferably has a length of about 30 mm, such as about 28 mm or 26 mm, a width of about 12 mm, such as about 10 mm or 8 mm, and a depth of about 5 mm, such as about 4 mm or 3 mm.

[0044] The smokeless article preferably has an active lifetime of about 20 minutes to about 60 minutes, such as about 25 minutes to 50 minutes or about 30 minutes to about 45 minutes, after being placed in the mouth. As used herein, the term "active lifetime" is intended to refer to the amount of time after being placed in the mouth that the smokeless article provides the user with a perceptible taste and/or physiological experience. For example, for an article containing an active ingredient such as nicotine or other pharmacologically active ingredient the active lifetime may be defined as the in use period of time in which 90%wt of the available pharmacologically active is released. In other words, the active lifetime may be the duration of time from insertion into the oral cavity for 90%wt of the total amount of nicotine pharmacologically active ingredient that is capable of being released during normal use to dissolve into the user's saliva and /or enter the user's bloodstream. It will therefore be appreciated that the active lifetime of a product may vary from user to user and for a user based on oral conditions, in particular extent of salivation. Nonetheless, the skilled person is able to mimic oral conditions to determine the active lifetime in one instance, which can be used as a comparison or analysis point.

[0045] The pouch may be formed from one or more materials. The pouch material may be formed from fiber, paper, cloth and fabric. The pouch material may be formed from one or more polymeric materials. The polymeric material may be selected from one or more of hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVOH), polyvinylpyrrolidone (PVP), polyethylene oxide (PEO) hydroxyethyl cellulose (HEC), polyethylene glycol (PEG), pullulan, sodium alginate, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, maltodextrin, methylmethacrylate copolymer, carboxyvinyl copolymers, starch and gelatin.

[0046] The pouch is typically completely insoluble in saliva. Suitable insoluble pouch materials include, but are not limited to, fiber, paper, water-insoluble polymers, cloth and fabric. Suitable soluble pouch materials include, but are not limited to, water-soluble polymers such as polyethylene oxide (PEO), hydroxypropyl cellulose (HPC) and hydroxypropyl methylcellulose (HPMC).

[0047] The pouch may be formed by, for example, folding a single sheet on itself or bringing two or more sheets together and sealing the edges. The edges may initially be partially sealed to provide an open pouch in which the content (e.g. bamboo fibres) may be placed before completely sealing the pouch closed. The sheets may be the same thickness or different thicknesses.

[0048] The pouch is porous. Preferably, at least 50% of the pores have a diameter of 50 μ m to 200 μ m, such as 100 μ m to 175 μ m or 125 μ m or 150 μ m. In some embodiments at least 50% of the pores have a diameter of at least 100 μ m. For example, at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the pores have such diameters. [0049] The pouch may be coloured or include markings, such as brand logos and text, to improve user perception. The pouch may be partially or completely coloured by a colourant.

[0050] The contents comprise nicotine-dosed bamboo fibres and may comprise one or more additional substances. [0051] The or each additional substance may individually be a biologically/pharmacologically active compound, pH stabilisers or adjusters, humectants, flavourants, fillers, preservatives, aqueous/non-aqueous solvents and binders. The or each additional substance may be provided for more than one purpose.

[0052] The contents of the pouch (i.e. the ingredients, material and/or substances enclosed within the pouch) preferably occupies substantially all of the internal volume of the pouch. The contents may occupy 80%, 85%, 90%, 95% or 100% of the internal volume of the pouch. The contents may comprise a solid material to provide physical integrity, such as an organic material (e.g. plant material) or an inorganic material. Such solid materials may naturally or inherently contain one or more biologically/pharmacologically active compounds and/or additives.

[0053] Biologically/pharmacologically active compounds are provided to produce a pharmacological effect in the user. Suitable biologically/pharmacologically active compounds include the group consisting of: nicotine, cocaine, caffeine, opiates and opioids, cathine and cathinone, kavalactones, mysticin, beta-carboline alkaloids, salvinorin A together with any combinations, functional equivalents to, and/or synthetic alternatives of the foregoing. Biologically/pharmacologically active compounds may also have additive properties.

[0054] In some embodiments the contents include an active compound comprising nicotine and wherein the form of nicotine is selected from the group consisting of nicotine salts, nicotine base, stabilized nicotine and mixtures thereof. For example, the contents may include at least one nicotine salt selected from the group consisting of nicotine hydrochloride, nicotine dihydrochloride, nicotine monotartrate, nicotine ditartrate, nicotine ditartrate dihydrate, nicotine sulfate, nicotine zinc chloride monohydrate, nicotine salicylate and mixtures thereof.

[0055] pH stabilisers or adjusters may be provided to adjust the user experience and/or modify the bioavailability of a pharmacologically active compound. For instance, under acidic conditions, nicotine is protonated and does not readily cross mucous membranes. Examples of suitable pH stabilisers include ammonia, ammonium carbonate, sodium carbonate and calcium carbonate. The overall pH of the smokeless article is preferably pH 7 to pH 9, such as pH 7.25 to pH 8.75 or pH 7.5 to pH 8.5.

30

35

45

50

[0056] The overall pH of a smokeless article may be determined by, for example, (i) placing the smokeless article in 10 mL of distilled water (ii) agitating the mixture for at least 5 minutes and (iii) measuring the pH of the solution with a pH probe.

[0057] Fillers may be provided to increase the volume of the smokeless article (e.g. by increasing the volume contained within the pouch and to strengthen the contents). Suitable fillers include calcium carbonate, calcium phosphate, corn starch, grains, lactose, polysaccharides (e.g. maltodextrin), polyols, sugars (e.g. dextrose, manitol, xylitol, sorbitol), natural fibres (e.g. non-tobacco fibres), microcrystalline cellulose, cellulose and cellulose derivatives (e.g. finely divided cellulose), lignocellulose fibres (e.g. wood fibres), jute fibres and combinations thereof. In some cases, the filler content is 5 to 10 wt% of the contents e.g. around 6 to 9 wt%.

[0058] Flavourants may be provided in solid or liquid form. Suitable flavourants include coffee, eucalyptus, menthol, liquorice, peppermint, spearmint, chocolate, fruit flavour (including e.g. citrus, cherry etc.), vanilla, spice (e.g. ginger, cinnamon) and tobacco flavour. The flavourant may be evenly dispersed throughout the contents or may be provided in isolated locations and/or varying concentrations throughout the contents. As used herein, the term "flavourant" denotes a compound having a desirable taste, aroma or both.

[0059] Humectants may be provided to control moisture content thereby preventing the smokeless article from drying out during storage and reducing the amount of saliva wetting required before the user experience begins. Suitable humectants include polyhydric alcohols (e.g. propylene glycol (PG), triethylene glycol, 1,2-butane diol and vegetable glycerine (VG)) and their esters (e.g. glycerol mono-, di- or tri-acetate).

[0060] The humectant may have a lower limit of at least 1 % by weight of the contents such as at least 2 wt%, such as at least 2 wt%, such as at least 20 wt%, such as at least 30 wt%, or such as least 40 wt%. [0061] The humectant may have an upper limit of at most 50% by weight of the contents, such as at most 40 wt%, such as at most 30 wt%, or such as at most 20 wt%, such as at most 5 wt %, such as at most 5 wt %, such as at most 2 wt%.. [0062] Preferably, the amount of humectant is 1 to 40 wt% of the contents, such as 2 to 20 wt% or 5 to 10 wt%.

[0063] Preferably, the contents has an overall amount of water of between 5 and 50 wt% based on the weight of the contents such as between 10 to 20 wt% or 40 to 50 wt%.

[0064] Smokeless articles having a total moisture content of 10% or less are generally considered to be 'dry'. Smokeless articles having a total moisture content of 40% or more are generally considered to be 'wet'.

[0065] Sweeteners may be provided to modify the user taste perception and, in particular, overcome bitter flavours that result from other substances. Suitable sweeteners include honey, sugar, brown sugar, glucose, fructose, sucrose, aspartame, xylitol, maltitol, saccharin sodium, glycyrrhizin tripotassium liquorice, jujube or a mixture thereof. The amount of sweetener is in some cases 1 to 20 % by weight of the contents, such as 2 to 15 wt% or 5 to 10 wt%.

[0066] Stabilisers are provided to prevent decomposition or degradation overtime during storage by, for example, retarding oxidation or unwanted biological activity. Stabilisers may be selected from the group consisting of antioxidants including vitamin E, such as tocopherole, ascorbic acid, sodium pyrosulfite, butylhydroxytoluene, butylated hydroxyanisole, edetic acid and salts thereof; and preservatives including citric acid, tartaric acid, lactic acid, malic acid, acetic acid, benzoic acid, sorbic acid and salts thereof.

10

30

35

40

45

50

55

[0067] Binders may be provided. Suitable binders include starches and/or cellulosic binders such as methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose and carboxymethyl cellulose, gums such as xanthan, quar, arabic and/or locust bean qum, organic acids and their salts such as alginic acid (sodium alginate), agar and pectins. In some embodiments the binder content is 5 to 10 wt% of the contents, e.g. around 6 to 9 wt% or 7 to 8 wt%. [0068] Colourants may be provided to modify the user impression of the smokeless article. Colourants include whitening agents. Colourants may be selected from one or more of common colourants such as curcumin (E100), turmeric (E100(ii)), riboflavin (E101), riboflavin-5'-phosphate (E101(ii)), tartrazine (E102), quinoline yellow (E104), riboflavin-5sodium phosphate (E106), yellow 2G (E107), sunset yellow FCF (E110), carmine, cochineal (E120), azorubine (E122), amaranth (E123), ponceau 4R (E124), erythrosine (E127), red 2G (E128), allura red AC (E129), patent blue V (E131), indigotine (E132), brilliant blue FCF (E133), chlorophylls (E140), copper complexes of chlorophyll (E141), green S (E142), caramel (E150a-d), brilliant black BN (E151), carbon (E153), brown FK (E154), brown HT (E155), alfa-, beta- and gammacarotene (E160a), annatto, bixin, norbixin (E160b), bell pepper (Paprika) extract (E160c), lycopene (E160d), beta-apo-8'-carotenal (E160e), ethyl ester of beta-apo-8'-carotenic acid (E160f), flavoxanthin (E161a), lutein (E161b), cryptoxanthin (E161c), rubixanthin (E161d), violaxanthin (E161e), rhodoxanthin (E161f), canthaxanthin (E161g), citranaxanthin (E161h), beetroot extract (E162), anthocyanins (E163), calcium carbonate (E170), titanium dioxide (E171), iron oxides (E172), aluminium (E173), silver (E174), gold (E175), lithol rubine BK (E180), tannins (E181). The amount of colourant may be up to about 3% by weight of the smokeless article, such as about 0.5% to about 2.5% or about 1% to about 2%. [0069] Plant material in addition to the bamboo fibres may be provided for physical integrity and may function as a natural source of substances such as, for example, biologically/pharmacologically active compounds, flavourants, pH stabilisers etc. The plant material may comprise at least one plant material selected from the list including Amaranthus dubius, Arctostaphylos uva-ursi (Bearberry), Argemone mexicana, Amica, Artemisia vulgaris, Yellow Tees, Galea zacatechichi, Canavalia maritima (Baybean), Cecropia mexicana (Guamura), Cestrum noctumum, Cynoglossum virginianum (wild comfrey), Cytisus scoparius, Damiana, Entada rheedii, Eschscholzia californica (California Poppy), Fittonia albivenis, Hippobroma longiflora, Humulus japonica (Japanese Hops), Humulus lupulus (Hops), Lactuca virosa (Lettuce Opium), Laggera alata, Leonotis leonurus, Leonurus cardiaca (Motherwort), Leonurus sibiricus (Honeyweed), Lobelia cardinalis, Lobelia inflata (Indian-tobacco), Lobelia siphilitica, Nepeta cataria (Catnip), Nicotiana species (Tobacco), Nymphaea alba (White Lily), Nymphaea caerulea (Blue Lily), Opium poppy, Passiflora incamata (Passionflower), Pedicularis densiflora (Indian Warrior), Pedicularis groenlandica (Elephant's Head), Salvia divinorum, Salvia dorrii (Tobacco Sage), Salvia species (Sage), Scutellaria galericulata, Scutellaria lateriflora, Scutellaria nana, Scutellaria species (Skullcap), Sida acuta (Wireweed), Sida rhombifolia, Silene capensis, Syzygium aromaticum (Clove), Tagetes lucida (Mexican Tarragon), Tarchonanthus camphoratus, Tumera diffusa (Damiana), Verbascum (Mullein), Zamia latifolia (Maconha Brava) together with any combinations, functional equivalents to, and/or synthetic alternatives of the foregoing.

[0070] The plant material may be tobacco. Any type of tobacco may be used. This includes, but is not limited to, flue-cured tobacco, burley tobacco, Maryland Tobacco, dark-air cured tobacco, oriental tobacco, dark-fired tobacco, perique tobacco and rustica tobacco. This also includes blends of the above mentioned tobaccos.

[0071] Any suitable parts of the tobacco plant may be used. This includes leaves, stems, roots, bark, seeds and flowers. [0072] The tobacco may comprise one or more of leaf tobacco, stem tobacco, tobacco powder, tobacco dust, tobacco derivatives, expanded tobacco, homogenised tobacco, shredded tobacco, extruded tobacco, cut rag tobacco and/or reconstituted tobacco (e.g. slurry recon or paper recon).

[0073] The contents may comprise at least 50 wt% plant material based on the weight of the contents, e.g. at least 60 wt% plant material e.g. around 65 wt% plant material. The contents may comprise 80 wt% or less plant material e.g. 75 or 70 wt% or less plant material.

[0074] The contents may comprise a gathered sheet of homogenised (e.g. paper/slurry recon) tobacco orgathered shreds/strips formed from such a sheet.

[0075] The sheet may have a grammage greater than or equal to 100 g/m^2 , e.g. greater than or equal to 110 g/m^2 such as greater than or equal to 120 g/m^2 . The sheet may have a grammage of less than or equal to 300 g/m^2 e.g. less than or equal to 250 g/m^2 or less than or equal to 200 g/m^2 . The sheet may have a grammage of between $120 \text{ and } 190 \text{ g/m}^2$.

[0076] The skilled person will appreciate that except where mutually exclusive, a feature or parameter described in relation to any one of the above aspects may be applied to any other aspect. Furthermore, except where mutually exclusive, any feature or parameter described herein may be applied to any aspect and/or combined with any other feature or parameter described herein.

Summary of the Figures

5

10

15

25

30

35

40

[0077] So that the invention may be understood, and so that further aspects and features thereof may be appreciated, embodiments illustrating the principles of the invention will now be discussed in further detail with reference to the accompanying figures, in which:

- Figure 1 shows a cross sectional view of a first embodiment of a smokeless article.
- Figure 2 shows a cross sectional view of a second embodiment of a smokeless article.
- Figure 3 shows a cross sectional view of a third embodiment of a smokeless article.
- Figure 4 shows a cross sectional view of a fourth embodiment of a smokeless article.
- ²⁰ Figure 5 shows a plot of nicotine release rate for two embodiments of the invention and two comparative compositions.

Detailed Description of the Figures

[0078] As shown in Figure 1 there is provided a first embodiment of a smokeless article 10 having a pouch 12 containing contents 14. The pouch 12 is substantially rectangular. The pouch 12 is formed from a single sheet of material and is substantially filled by the contents 14. The pouch 12 has a seal 16 along each of the three edges where the inner face of the single sheet meets itself to seal the contents 14 in the pouch 12.

[0079] Figure 2 shows a second embodiment of a smokeless article 10' having a pouch 12 containing contents 14. The pouch 12 is substantially circular. The pouch 12 is formed from two opposing sheets of material and is substantially filled by the contents 14. The pouch has a circumferential seal 16 along the edges where the two opposing sheets of material meet to seal the contents 14 in the pouch 12.

[0080] Figure 3 shows a third embodiment of a smokeless article 10" that, like the first embodiment, has a pouch 12 made from a single sheet of material. However, one of the three seals 16' is formed by an overlap of the inner face and the outer face of the single sheet meet to seal the contents 14 in the pouch 12. The remaining two seals at opposing ends of the pouch 12 are formed where the inner face of the single sheet meets itself.

[0081] Figure 4 shows a fourth embodiment of a smokeless article 10" that comprises the third embodiment enclosed by outer pouch 12" having an outer contents 14" positioned in the space between the inner pouch 12' and the outer pouch 12". The outer pouch 12" also has a circumferential seal 16" to seal the outer contents 14" and inner pouch 12' in the outer pouch 12".

[0082] Use of the fourth embodiment begins when the smokeless article 10" is placed in the user's mouth where it is exposed to saliva. Saliva first permeates outer pouch 12" and dissolves and extracts the saliva soluble substances of outer contents 14". Upon leaving the outer pouch 12", the saliva soluble substances of outer contents 14" therefore provide the user with a first experience. Saliva subsequently further permeates the inner pouch 12' where it dissolves and extracts the saliva soluble substances of inner contents 14'. The saliva soluble substances of inner contents 14' therefore provide the user with a complimentary and secondary experience. When the extractable amount of saliva soluble substances in the inner contents 14' and outer contents 14" drops below perceivable levels the active lifetime of the smokeless article 10'" has ended.

Examples

[0083] Various snus samples were prepared and tested for nicotine release rate.

[0084] Sample 1 was prepared containing bamboo fibres with a maximum length of 30 μ m (JELUCEL® BF-30 fibres ex Jelu-werk). Sample 1 contained the following components:

| Ingredient | Content / g | | |
|--------------------------------|-------------|--|--|
| Nicotine ditartarate dihydrate | 1.40 | | |

55

50

(continued)

| Ingredient | Content / g |
|----------------------------|-------------|
| Bamboo fibres (30 μm) | 56.02 |
| Salt | 4.20 |
| Water | 30.00 |
| Ammonium chloride solution | 2.03 |
| Propylene glycol | 3.65 |
| Sodium carbonate solution | 0.41 |
| Flavour (mint) | 2.30 |
| Total | 100 |

[0085] One further sample, Sample 2, was prepared which contained bamboo fibres with a maximum length of 300 μ m (JELUCEL® BF-300 fibres ex Jelu-werk).

[0086] Sample 2 contained the following components:

| Ingredient | Content / g |
|--------------------------------|-------------|
| Nicotine ditartarate dihydrate | 1.40 |
| Bamboo fibres (300 μm) | 56.02 |
| Salt | 4.20 |
| Water | 30.00 |
| Ammonium chloride solution | 2.03 |
| Propylene glycol | 3.65 |
| Sodium carbonate solution | 0.41 |
| Flavour (mint) | 2.30 |
| Total | 100 |

[0087] In addition to these, as comparative articles, commercially available Skruf #3 and Lyft #3 samples were tested. Comparative Sample 1 was Skruf #3, a commercially available smokeless article which includes wheat fibres with a maximum particle size of 200 μ m. Comparative Sample 2 was Lyft #3, a commercially available smokeless article which includes eucalyptus and pine fibres.

[0088] The samples were tested by immersing each of the samples in the same model solution representing human saliva. The model solution was made with deionised water containing the following ingredients:

| Ingredient | Content (g/1000mL) |
|--|--------------------|
| Magnesium chloride hexahydrate | 0.17 |
| Potassium hydrogen phosphate anhydrous | 0.68 |
| Sodium chloride | 0.33 |
| Potassium chloride | 0.75 |
| Calcium chloride dehydrate | 0.15 |
| Potassium carbonate | 0.53 |
| Hydrochloric acid | to pH 6.8 ± 0.1 |

[0089] The model solution was prepared by mixing all ingredients in the table except hydrochloric acid and transferring to a 2 L glass reservoir. 500 mL of deionised water was added and the solution was mixed well to dissolve. Further

deionised water was added to bring the total amount of deionised water added to 1 L. The reservoir was sealed and mixed well. The pH was then adjusted to 6.8 by the addition of HCI. The solution was used within 2 days of preparation. [0090] Nicotine concentration in the model solution was determined at certain time intervals by UV-vis using USP 4 flow-through dissolution apparatus with online UV system, thereby providing an indication of the rate of release of nicotine from the immersed pouch.

[0091] Figure 5 is a plot showing the results of nicotine release tests for the smokeless articles of the invention and the comparative articles.

[0092] Samples 1 and 2 demonstrated significantly improved nicotine release characteristics over the comparative articles. For Sample 1 containing 30 μ m fibres, more than 80 wt% of the nicotine content was released after 20 minutes, compared with only around 45-60 wt% for the comparative articles. For Sample 2 containing 300 μ m fibres, more than 90 wt% of the nicotine content was released after 20 minutes.

[0093] The features disclosed in the foregoing description, or in the following claims, or in the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for obtaining the disclosed results, as appropriate, may, separately, or in any combination of such features, be utilised for realising the invention in diverse forms thereof.

[0094] While the invention has been described in conjunction with the exemplary embodiments described above, many equivalent modifications and variations will be apparent to those skilled in the art when given this disclosure. Accordingly, the exemplary embodiments of the invention set forth above are considered to be illustrative and not limiting. Various changes to the described embodiments may be made without departing from the scope of the invention.

[0095] For the avoidance of any doubt, any theoretical explanations provided herein are provided for the purposes of improving the understanding of a reader. The inventors do not wish to be bound by any of these theoretical explanations.

[0096] Any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0097] Throughout this specification, including the claims which follow, unless the context requires otherwise, the words "have", "comprise", and "include", and variations such as "having", "comprises", "comprising", and "including" will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[0098] It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by the use of the antecedent "about," it will be understood that the particular value forms another embodiment. The term "about" in relation to a numerical value is optional and means, for example, +/- 10%.

[0099] The words "preferred" and "preferably" are used herein refer to embodiments of the invention that may provide certain benefits under some circumstances. It is to be appreciated, however, that other embodiments may also be preferred under the same or different circumstances. The recitation of one or more preferred embodiments therefore does not mean or imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the disclosure, or from the scope of the claims.

Claims

10

15

20

30

35

40

45

- 1. A smokeless article for oral consumption comprising a pouch enclosing a content, the content comprising nicotine-dosed bamboo fibres, wherein the bamboo fibres have a particle size of 10-500 μ m.
- 2. The smokeless article according to claim 1, wherein the bamboo fibres have a particle size of 30-300 μm .
- 3. The smokeless article according to claim 1, wherein the bamboo fibres have a particle size of about 30 μm.
- 50 **4.** The smokeless article according to claim 1, wherein the bamboo fibres have a particle size of about 300 μm.
 - 5. The smokeless article according to any one of claims 1 to 4, wherein the nicotine-dosed bamboo fibres comprise a nicotinic compound selected from nicotine, nicotine salt(s), nicotine complex(es); and nicotine solvate(s).
- 55 **6.** The smokeless article according to claim 5, wherein the nicotinic compound is provided in a plant material.
 - 7. The smokeless article of claim 6, wherein the plant material is tobacco.

- 8. The smokeless article according to any one of claims 1 to 6, wherein the smokeless article is tobacco-free.
- **9.** The smokeless article according to any one of claims 1 to 8, wherein the total nicotine content is from 5 to 15 mg, preferably about 10 mg.
- **10.** The smokeless article according to any one of claims 1 to 9, wherein greater than 75 wt%, preferably greater than 80 wt%, of the total nicotine content of the smokeless article is released from the smokeless article after 20 minutes immersed in water.
- 10 11. The use of nicotine-dosed bamboo fibres, wherein the bamboo fibres have a particle size of 10-500 μ m, as a nicotine release accelerant in a smokeless article for oral consumption.
 - 12. The use of nicotine-dosed bamboo fibres, wherein the bamboo fibres have a particle size of 10-500 μ m, to increase manufacturing capacity of a smokeless article and/or reduce manufacturing cost.
 - 13. The use according to claim 11 or 12 wherein the smokeless article is according to any one of claims 1 to 10.
 - 14. A method of manufacturing a smokeless article according to any one of claims 1 to 10 comprising the steps of;
 - (i) forming one or more sheets of pouch material around the contents; and

5

15

20

25

30

35

40

45

50

55

- (ii) thermally or chemically sealing the pouch material to enclose the contents.
- **15.** A kit comprising a plurality of smokeless articles according to any one of claims 1 to 10 and a container.

10




Figure 1




Figure 2




Figure 3





Figure 4





EUROPEAN SEARCH REPORT

Application Number EP 20 15 8075

5

| To a legory of relevant passages to claim AF US 2011/247640 A1 (BEESON DWAYNE WILLIAM 1,2,4-7, IN [US] ET AL) 13 October 2011 (2011-10-13) 10-15 A2 | CLASSIFICATION OF THE APPLICATION (IPC) [NV.] A24B13/00 A24B15/16 |
|---|--|
| US] ET AL) 13 October 2011 (2011-10-13) 10-15 A2 | A24B13/00 |
| 12, 27 | , |
| X W0 2019/115778 A1 (SWEDISH MATCH NORTH EUROPE AB [SE]) 20 June 2019 (2019-06-20) * page 8; claims 1, 2, 28, 29, 33, 42 * | |
| X NO 343 402 B1 (SWEDISH MATCH NORTH EUROPE AB [SE]) 25 February 2019 (2019-02-25) 8,10-15 page 6, line 7 - line 9; claims 1,8 * page 2, line 1 - line 4 * | |
| X SE 540 813 C2 (SWEDISH MATCH NORTH EUROPE AB [SE]) 20 November 2018 (2018-11-20) 8,10-15 page 6, line 7 - line 9; claims 1,8 * page 2, line 1 - line 4 * | |
| * paragraphs [0043], [0056] - [0061], s | TECHNICAL FIELDS SEARCHED (IPC) |
| X WO 2015/051306 A1 (ALTRIA CLIENT SERVICES INC [US]) 9 April 2015 (2015-04-09) * page 31 - page 32; claims 1,26 * | |
| X W0 2018/197454 A1 (SWEDISH MATCH NORTH EURO AB) 1 November 2018 (2018-11-01) * page 7, line 1 - line 7; claims 1,12,16 * | |
| X US 2015/020818 A1 (GAO FENG [US] ET AL) 22 January 2015 (2015-01-22) * paragraphs [0013], [0025], [0026], [0030]; claim 1 * | |
| 45 | |
| The present search report has been drawn up for all claims | |
| Place of search Date of completion of the search E | Examiner Anyi Kelemen, K |
| CATEGORY OF CITED DOCUMENTS T: theory or principle underlying the invention | |
| The Hague CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the inventic E: earlier patent document, but published of after the filling date D: document ofted in the application L: document ofted in the application Coument of the same patent family, corredocument A: member of the same patent family, corredocument | d on, or |

55

page 1 of 2



EUROPEAN SEARCH REPORT

Application Number EP 20 15 8075

5

| | | DOCUMENTS CONSID | ERED TO BE RELE | VANT | | |
|-------------|--|---|---|---|---|---|
| | Category | Citation of document with in of relevant pass | ndication, where appropriate ages | | Relevant o claim | CLASSIFICATION OF THE APPLICATION (IPC) |
| 10 | X | WO 2013/152918 A1 (EUROPE AB [SE]) 17 October 2013 (20 * examples; paragraph [0030]; c | 013-10-17) | RTH 1, | 2,5-7, 15 | |
| 15 | | | | | | |
| 20 | | | | | | |
| 25 | | | | | | TECHNICAL FIELDS SEARCHED (IPC) |
| 30 | | | | | | |
| 35 | | | | | | |
| 40 | | | | | | |
| 45 | | The present search report has | been drawn up for all claims | | | |
| | | Place of search | Date of completion of | | | Examiner |
| Š | <u> </u> | The Hague | 20 August | 2020 | Vil | lányi Kelemen, K |
| 50 88 88 PM | X: parl Y: parl door A: tech O: nor P: inte | ATEGORY OF CITED DOCUMENTS ioularly relevant if taken alone ioularly relevant if combined with anot ument of the same category inological background i-written disclosure rmediate document | E : earl afte her D : doc L : doc & : mer | ory or principle undi ier patent documer the filing date ument cited in the a ument cited for othe mber of the same p ument | nt, but publis application er reasons | hed on, or |

55

page 2 of 2

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 20 15 8075

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-08-2020

| 10 | Patent document cited in search report | | Publication date | Patent memb | | Publication date |
|----------|--|----|---------------------|---|--|--|
| 15 | US 2011247640 | A1 | 13-10-2011 | EP 255 ES 254 JP 586 JP 201352 US 201124 US 201518 US 201931 | 3102 A 5641 A1 1490 T3 8941 B2 3163 A 7640 A1 9909 A1 3689 A1 7182 A1 | 13-02-2013 13-02-2013 21-07-2015 24-02-2016 17-06-2013 13-10-2011 09-07-2015 17-10-2019 13-10-2011 |
| | WO 2019115778 | A1 | 20-06-2019 | CA 308 | 5204 A1 5778 A1 | 20-06-2019 20-06-2019 |
| 25 | NO 343402 | В1 | 25-02-2019 | NONE | | |
| | SE 540813 | C2 | 20-11-2018 | | 0813 C2 0488 A1 | 20-11-2018 25-10-2018 |
| 30 | US 2015096573 | Α1 | 09-04-2015 | NONE | | |
| | WO 2015051306 | A1 | 09-04-2015 | NONE | | |
| 35 | WO 2018197454 | A1 | 01-11-2018 | US 202012 | 4869 A1 8870 A1 7454 A1 | 04-03-2020 30-04-2020 01-11-2018 |
| 40 45 | US 2015020818 | A1 | 22-01-2015 | EP 302 EP 362 ES 275 JP 201652 JP 201915 US 201502 US 201709 US 201932 | 8271 A1 1691 A1 2834 A1 9227 T3 4916 A 0032 A 0818 A1 9868 A1 8032 A1 9913 A1 | 22-01-2015 25-05-2016 18-03-2020 08-05-2020 22-08-2016 12-09-2019 22-01-2015 13-04-2017 31-10-2019 22-01-2015 |
| 50 | WO 2013152918 | A1 | 17-10-2013 | DK 264 DK 283 EP 264 EP 283 RU 201414 US 201507 | 5683 A1 9888 T3 6088 T3 9888 A1 6088 A1 2551 A 5543 A1 2918 A1 | 17-10-2013 27-04-2020 06-06-2016 16-10-2013 18-02-2015 10-06-2016 19-03-2015 17-10-2013 |
| 55 | OH OH | | | | | |

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

• **RUTQVIST.** Swedish snus and the GothiaTek® standard, 2005 [0009]